News
Poxel Announces Results from June 21, 2023 Ordinary Annual and Extraordinary General Meeting
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Vistagen Regains Full Compliance with Nasdaq Listing Requirements
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East
RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement
Pfizer Declares Third-Quarter 2023 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 third-quarter 2023 dividend on the company’s common stock, payable September 5, 2023, to holders of the Common
Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea
Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval
Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with
OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi® in Non-Small Cell Lung Cancer
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Company has received €1.5 million in non-dilutive funding from Bpifrance - Direction
Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 1, 2023. The purpose
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced three oral presentations at the Annual Meeting of the European Renal Association (ERA), providing additional
Almirall launches Nina, the first series to highlight the major impact of psoriasis on patient’s wellbeing
Psoriasis is a chronic dermatological disease that not only affects the skin but also their mental and social wellbeing. The disease has an impact on all aspects of daily lives and almost 77% of
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
Cosmo Pharmaceuticals announces approval of Winlevi® in Canada
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Anniversary of BRAIN Biotech AG: 30 years for a bio-based future
Sensorion Reports Promising Preliminary Data from SENS-401 Phase 2a Clinical Study
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Vistagen to Participate in the Maxim Group Healthcare Virtual Conference Hosted by M-Vest
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement
EQS-News: Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023
OSE Immunotherapeutics Presents Update on BiCKI®IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presents scientific updates in oral and poster presentations selected for international conferences: at the Antibody
Poxel Announces its Participation at Patient Association Conferences in Adrenoleukodystrophy
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic